ScholarIQanswers from OpenAlex & ORCID
Rodolfo F. Perini
ResearcherPublications, citations & collaboration network
Rodolfo F. Perini is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Rodolfo F. Perini have?
ScholarIQindexed works
Rodolfo F. Perini has 242 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Rodolfo F. Perini have?
ScholarIQcitation count
Rodolfo F. Perini has 16,297 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Rodolfo F. Perini?
ScholarIQh-index
Rodolfo F. Perini has an h-index of 38 in OpenAlex.
What is the i10-index of Rodolfo F. Perini?
ScholarIQi10-index
Rodolfo F. Perini has an i10-index of 96 in OpenAlex.
What is the ORCID of Rodolfo F. Perini?
ScholarIQorcid
The ORCID for Rodolfo F. Perini is on the source record.
What is the OpenAlex record for Rodolfo F. Perini?
ScholarIQopenalex
The OpenAlex for Rodolfo F. Perini is on the source record.
What are the most-cited papers on Rodolfo F. Perini?
ScholarIQmost cited works
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Grünwald, Thomas E. Hutson, Evgeny Kopyltsov, María José Méndez-Vidal, Vadim Kozlov, Anna Alyasova, Sung‐Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frédéric Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer, Ugo De Giorgi, Tomáš Büchler, Naveen S. Basappa, María José Méndez-Vidal, Sergei Tjulandin, Se Hoon Park, Bohuslav Melichar, Thomas E. Hutson, C. Alemany, Bradley A. McGregor, Thomas Powles, Viktor Grünwald, B. Yа. Alekseev, Sun Young Rha, Evgeny Kopyltsov, Anil Kapoor, Teresa Alonso Gordoa, Jeffrey C. Goh, Michael Staehler, Jaime R. Merchan, Ran Xie, Rodolfo F. Perini, Kalgi Mody, Jodi A. McKenzie, Camillo Porta